TiGenix to present positive 52-week Phase III Cx601 data at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
31
TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

PRESS RELEASE

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

Leuven (BELGIUM) - November 20, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions , today announces that the positive 52-week results from its ADMIRE-CD Phase III clinical trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease will be presented at the EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy taking place from November 23-25, 2017 in Amsterdam, Netherlands. TiGenix is a contributor of the meeting.

Presentation Title: Allogeneic adipose-derived MSC for complex perianal fistulas in Crohn's disease 

Session Date: Friday, November 24, 2017

Session Time: 13:30 - 15:30 Scientific session: Clinical Trials

Presenter: Pr. Damian Garcia Olmo, MD

"We are looking forward to presenting positive 52-week results from the ADMIRE-CD Phase III trial demonstrating the long-term efficacy and safety of Cx601 for complex perianal fistulas in Crohn's disease patients at this key scientific meeting," said Dr. Mary Carmen Diez, Vice President, Medical Affairs and Commercialisation at TiGenix. "These data have been used to support our marketing authorisation application for Cx601, for which we anticipate a CHMP opinion in 2017. TiGenix is proud to support this exciting meeting, which brings together science and clinical research for novel advanced therapy medicinal products."

For more information please contact:

TiGenix Claudia Jiménez Senior Director Investor Relations and Communications Tel: +34918049264 Claudia.jimenez@tigenix.com  

PR Enquiries Consilium Strategic Communications Chris Gardner, Sukaina Virji, Melissa Gardiner Tel: +44 (0)20 3709 5700 TiGenix@consilium-comms.com      

About TiGenix

TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells .

TiGenix lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. Cx601 has been filed for regulatory approval in Europe and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. Finally, AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive results in a Phase I/II trial in acute myocardial infarction (AMI). TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit http://www.tigenix.com .

About Cx601

Cx601 is a local administration of allogeneic (or donor derived) expanded adipose-derived stem cells (eASCs) for the treatment of complex perianal fistulas in Crohn's disease patients that have previously failed conventional therapy. Crohn's disease is a chronic inflammatory disease of the intestine and complex perianal fistulas are a severe and debilitating complication for which there is currently no effective treatment. Cx601 was granted orphan drug designation by the European Commission in 2009 and by the U.S. Food and Drug Administration (FDA) in 2017. TiGenix completed a European Phase III clinical trial (ADMIRE-CD) in August 2015 in which both the primary endpoint and the safety and efficacy profile were met, with patients receiving Cx601 showing a 44% greater probability of achieving combined remission compared to control (placebo). A follow-up analysis was completed at 52 weeks and 104 weeks post-treatment, confirming the sustained efficacy and safety profile of the product [i] . The 24-week results of the Phase III ADMIRE-CD trial were published in The Lancet  in July 2016 [ii] .   Based on the positive 24 weeks Phase III study results, TiGenix submitted a Marketing Authorization Application to the European Medicines Agency (EMA) and a CHMP opinion is expected in 2017. A global Phase III clinical trial (ADMIRE-CD II) intended to support a future U.S. Biologic License Application (BLA) started in 2017, based on a trial protocol that has been agreed with the FDA through a special protocol assessment procedure (SPA) ( clinicaltrials.gov ; NCT03279081). ADMIRE-CD II is a randomized, double-blind, placebo-controlled study designed to confirm the efficacy and safety of a single administration of Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients. In July 2016, TiGenix entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired exclusive rights to develop and commercialize Cx601 for complex perianal fistulas in Crohn's patients outside of the U.S.

           

[i] Panes, J. et al. OP009 Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial. J Crohn's Colitis . 2017; 11: S5-S5.

[ii] Panés J, García-Olmo D, Van Assche G et al., Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomized, double-blind controlled trial. The Lancet. 2016; 388(10051):1281-90.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 0

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 44

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 74

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 165

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 34

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 159

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 57

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 42

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Swinerton Strengthens Leadership in Design-Build Initiatives

Updated Category News Views 250

Swinerton Welcomes Jason Bone as New Design-Build Leader In an exciting development, Swinerton Incorporated has bolstered its design-build leadership by appointing Jason Bone as the Director of National Design-Build. With this strategic move, the company reaffirms its dedication to providing exceptional client experiences while adapting to the evolving demands of the...

Continue Reading
PayPoint plc Announces PDMR Shareholding Updates

Updated Category News Views 144

PayPoint plc PDMR Share Acquisitions The company, PayPoint plc, recently shared exciting news regarding the shareholdings of its key executives, known as Persons Discharging Managerial Responsibilities (PDMRs). These PDMRs are significant players in the company, including its Executive Directors, and they participate in the Share Incentive Plan (SIP) designed to encourage...

Continue Reading
UMH Properties Announces First Quarter 2025 Financial Insights

Updated Category News Views 349

UMH Properties Reports Strong First Quarter Results for 2025 UMH Properties, Inc. (NYSE: UMH) recently revealed its financial results for the first quarter of 2025, showcasing encouraging growth and improvement in various operational metrics. The company reported a total income of $61.2 million for the quarter ending March 31, 2025, reflecting a 6% increase compared to...

Continue Reading
Netcompany Group Launches Share Buyback to Enhance Value

Updated Category News Views 245

Share Buyback Program Update from Netcompany Group Company announcement No. 20/2025 1 September 2025 On 14 August 2025, Netcompany Group A/S announced the initiation of a share buyback program of up to DKK 500 million, aiming to repurchase a total of 3,700,000 shares. This strategic move is designed to adjust the company’s capital structure while also fulfilling...

Continue Reading
Marex Group Investors: Join the Securities Fraud Class Action

Updated Category News Views 190

Recent Class Action Notice for Marex Group plc Investors In a significant announcement, a class action lawsuit has been filed that could impact many investors in Marex Group plc (NASDAQ: MRX). This legal action arises from reports that raise serious allegations regarding the company's financial reporting practices. For those who bought Marex shares, this is a crucial time...

Continue Reading